Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.

[1]  K. Kaira,et al.  Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status , 2021, Medicina.

[2]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[3]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[4]  Page Widick,et al.  Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy , 2021, JAMA network open.

[5]  J. Schachter,et al.  Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma , 2020, Cancers.

[6]  Michael L. Wang,et al.  Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials , 2020, JAMA network open.

[7]  K. Kiura,et al.  Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status , 2020, Cancer science.

[8]  L. Jones,et al.  Performance Status in Cancer: Not Broken, But Time for an Upgrade? , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Galetta,et al.  Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab , 2020, Acta oncologica.

[10]  J. Heymach,et al.  Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status , 2020, Journal for ImmunoTherapy of Cancer.

[11]  L. Landi,et al.  First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. , 2020, European journal of cancer.

[12]  L. Billingham,et al.  Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. , 2020, The Lancet. Respiratory medicine.

[13]  J. Temel,et al.  Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors , 2020, Cancer.

[14]  B. Escudier,et al.  Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial. , 2020 .

[15]  J. Milanowski,et al.  CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. , 2020, European journal of cancer.

[16]  U. Topaloglu,et al.  Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer. , 2020, Clinical lung cancer.

[17]  G. Sonpavde,et al.  Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors , 2019, Cancer.

[18]  S. Freedland,et al.  Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status , 2019, American journal of clinical oncology.

[19]  A. Addeo,et al.  Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era , 2019, Current Oncology Reports.

[20]  R. Lewinson,et al.  The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors , 2019, Cancers.

[21]  L. Einhorn,et al.  Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153). , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  T. Powles,et al.  Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. , 2019, European urology.

[23]  Yuanyuan Zhang,et al.  Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis , 2019, BMC Cancer.

[24]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[25]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[26]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Sok,et al.  Objective assessment of WHO/ECOG performance status , 2019, Supportive Care in Cancer.

[28]  S. Barni,et al.  Patient performance status and cancer immunotherapy efficacy: a meta-analysis , 2018, Medical Oncology.

[29]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[30]  E. Felip,et al.  Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[31]  D. Milne,et al.  Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death‐1 monoclonal antibodies for advanced melanoma , 2017, Asia-Pacific journal of clinical oncology.

[32]  R. Jang,et al.  Simple prognostic model for patients with advanced cancer based on performance status. , 2014, Journal of oncology practice.

[33]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[34]  Y. Shen,et al.  Imbalance of circulating T-lymphocyte subpopulation in gastric cancer patients correlated with performance status. , 2013, Clinical laboratory.

[35]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.